DUBLIN--(BUSINESS WIRE)--The "SNP Genotyping Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The global SNP genotyping market is expected to register a CAGR of 21% during the forecast period.

The analysis of SNPs is widely utilized in different disciplines of genetics and related studies, commonly associated with studying genetic determinants of many complex diseases. SNP technologies are extensively utilized for detection and are beneficial in the etiology of several human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, among others.

Companies Mentioned

Key Market Trends

Pharmacogenomics Led the End-user Segment of the SNP Genotyping Market

Under end users, pharmacogenomics is the leading segment. The large share of pharmacogenomics is primarily due to the increasing pipeline for personalized medicine and novel drug delivery systems, which are extensively exploiting SNP in genetic materials for drug development applications. According to the Journal of Personalized Medicine, up to June 2019, there were around 132 pharmacogenimic guidelines for the available drugs and also, pharmacogenomic information is added in around 309 medication label. Hence, the growing demand for pharmacogenomics is expected to propel the SNP Genotyping market in this segment.

North America had Largest Share in the Global SNP Market, while Asia-Pacific is the Fastest-growing Region

North America is the dominating region in the SNP genotyping market, due to rising commercial research in personalized medicines and animal breeding, among others. In addition, Asia-Pacific is the fastest-growing market, due to the rising demand for SNP genotyping in emerging economies like China and India, across different fields, which is largely propelling the market's growth.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Miniaturisation of Equipment and Instruments

4.2.2 Increased Multiplexing Capacity Leading to Increased Application

4.3 Market Restraints

4.3.1 Lack of Standardisation in SNP Processes

4.3.2 Privacy Concerns Pose a Threat to Broad Technology Adoption

4.4 Porter's Five Forces Analysis

5 MARKET SEGMENTATION

5.1 Technology

5.1.1 TaqMan SNP Genotyping

5.1.2 Massarray SNP Genotyping

5.1.3 SNP GeneChip Arrays

5.1.4 Other Technologies

5.2 End User

5.2.1 Pharmacogenomics

5.2.2 Diagnostic Field

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle-East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle-East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies Inc.

6.1.2 Bio-Rad Laboratories Inc.

6.1.3 Danaher Corporation

6.1.4 Douglas Scientific LLC

6.1.5 Illumina Inc.

6.1.6 Life Technologies Corp.

6.1.7 Luminex Corp.

6.1.8 Promega Corporation

6.1.9 Thermo Fischer Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/s2295f

Follow this link:

Worldwide SNP Genotyping Industry to 2025 - Pharmacogenomics Led the End-user Segment of the SNP Genotyping Market - ResearchAndMarkets.com - Business...